{"denoms":[{"counts":[{"groupId":"BG000","value":"52"}],"units":"Participants"}],"groups":[{"description":"AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)","id":"BG000","title":"AZD6244"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"20-29 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"30-39 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"40-49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"70-79 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"80-89 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eligible and treated patients."}